… with metastatic colorectal cancer and poor performance status… Eastern Cooperative Oncology
Group performance status ≥2. … metastatic colorectal cancer patients with poor performance …

… for patients with metastatic cancer. Patients with a poor performance status represent a …
of up to 41% of routine care metastatic colorectal cancer (mCRC) patients presenting with …

… Performance status (PS) is a prognostic factor in patients with metastatic colorectal cancer.
Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the benefit of …

… In the present study, palliative multiagent chemotherapy in poor performance status patients
with non-molecularly selected colorectal cancer tended to impact tumor symptoms control; …

… of patients with metastatic colorectal cancer (… performance.2, 3, 4 Currently we have scarce
data to evaluate whether such benefits apply equally to patients with poor performance status …

… We investigated Eastern Cooperative Oncology Group performance status in 502 patients
with mismatch repair deficient/ microsatellite instability-high metastatic colorectal cancer …

… Four rhythms known to reflect circadian clock function were studied in 18 patients with
metastatic colorectal cancer and good performance status. Rest–activity was monitored by wrist …

… with histologically proven metastatic colorectal cancer, referred for chronomodulated
chemotherapy, were registered in the study; 52% of the patients had two or more metastatic sites, …

… In this study, patients (pts) who were frail (ECOG 2) or older patients with ECOG 1 performance
status (PS) received CAP (1000 mg/m 2 bid, 14 days of every 21 days) plus BEV (7.5 mg/…

… for median overall survival in metastatic colorectal cancer [21]. In … population with a good
performance status, rather reflecting … for treatment of advanced metastatic cancer. Importantly, …